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Abstract
Background:  Gastric  cancer  is  the  second  cause  of  death  by  cancer  worldwide.  Histologic  clas-
siﬁcation may  predict  tumor  biology,  clinical  behavior,  and  outcome.  According  to  the  Lauren
classiﬁcation,  the  disease  is  divided  into  2  types,  diffuse  and  intestinal,  and  the  latter  has  a
better prognosis.
Aim:  To  determine  the  frequency  of  gastric  adenocarcinoma  and  compare  the  histopatho-
logic characteristics  of  intestinal  and  diffuse-type  gastric  adenocarcinoma  in  Mexican  patients
treated at  a  tertiary  referral  hospital.
Methodology:  A  retrospective  study  evaluated  the  pathology  reports  of  patients  with  gastric
adenocarcinoma  corresponding  to  the  time  frame  of  January  2003  to  December  2012.  Adeno-
carcinomas  of  the  gastric  cardia  were  excluded.  Frequencies  were  expressed  as  percentages
and the  categorical  variables  were  compared  with  the  chi-square  test.  Statistical  signiﬁcance
was set  at  a  P  <  .05.
Results:  A  total  of  417  cases  of  gastric  adenocarcinoma  were  found,  230  (55.2%)  of  which  were
diffuse-type  and  118  (28.2%)  were  intestinal-type.  The  mean  age  of  the  patients  with  diffuse
type gastric  cancer  was  54.02  ±  14.93  and  119  (51.3%)  of  those  patients  were  men.  The  mean
age of  the  patients  with  intestinal-type  gastric  cancer  was  63.43  ±  13.78,  and  69  (62.2%)  were
men. Ninety-two  of  the  diffuse-type  patients  were  under  the  age  of  50  years,  compared  with
22 of  the  patients  with  intestinal-type  carcinoma.
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Conclusions:  This  is  the  ﬁrst  study  on  the  Mexican  population  to  analyze  the  differences  in
the histologic  types  of  adenocarcinoma.  Diffuse-type  gastric  carcinoma  was  the  most  frequent
subtype in  our  study  population  and  it  is  associated  with  worse  outcome.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Características  histopatológicas  del  adenocarcinoma  gástrico  en  pacientes
mexicanos.  Experiencia  de  10  an˜os  en  el  Hospital  Juárez  de  México
Resumen
Antecedentes:  A  nivel  mundial  el  cáncer  gástrico  es  la  segunda  causa  de  muerte.  La  clasiﬁcación
histológica  puede  predecir  la  biología  del  tumor,  el  comportamiento  clínico  y  el  pronóstico.  De
acuerdo a  la  clasiﬁcación  de  Lauren,  se  divide  en  tipo  difuso  e  intestinal.  El  tipo  intestinal
muestra mejor  pronóstico  que  el  tipo  difuso.
Objetivo:  Determinar  la  frecuencia  de  adenocarcinoma  gástrico  y  comparar  las  características
histopatológicas  de  los  subtipos  de  adenocarcinoma  gástrico  intestinal  y  difuso  en  pacientes
mexicanos tratados  en  un  centro  de  referencia  de  tercer  nivel.
Metodología:  Estudio  retrospectivo  en  el  que  se  evaluaron  informes  patológicos  de  pacientes
con adenocarcinoma  gástrico  de  enero  del  2003  hasta  diciembre  del  2012.  Se  excluyeron  los
adenocarcinomas  del  cardias.  Las  frecuencias  se  expresaron  con  porcentajes  y  las  variables
categóricas  se  compararon  con  la  prueba  de  ji  cuadrado.  Los  valores  de  p  <  0.05  se  consideraron
como signiﬁcativos.
Resultados:  Se  encontraron  417  casos  de  adenocarcinoma  gástrico.  Hubo  230  (55.2%)  con
tipo difuso  y  118  (28.2%)  con  tipo  intestinal.  La  edad  media  en  el  tipo  difuso  fue  54.02  ±
14.93 an˜os  de  los  cuales  119  (51.3%)  fueron  hombres,  y  la  de  tipo  intestinal  fue  63.43  ±  13.78,
y 69  (62.2%)  fueron  hombres.  Entre  el  carcinoma  de  tipo  difuso,  92  fueron  menores  de  50  an˜os
en comparación  con  22  con  carcinoma  de  tipo  intestinal.
Conclusiones:  Este  es  el  primer  estudio  en  nuestra  población  que  hace  diferencias  entre  los
tipos histológicos  del  adenocarcinoma.  El  subtipo  de  adenocarcinoma  gástrico  más  frecuente
en nuestra  población  fue  el  difuso,  el  cual  se  asocia  a  peor  pronóstico.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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ntroduction
astric  cancer  is  the  second  cause  of  death  by  cancer
orldwide.1 In  2012,  the  World  Health  Organization  esti-
ated  about  one  million  new  cases  of  gastric  cancer
952,000  cases,  6.8%  of  all  cancers),  putting  it  in  ﬁfth  place
or  malignant  neoplasias,  after  lung,  breast,  colorectal,  and
rostate  cancers;  more  than  70%  of  the  cases  (677,000  cases)
ccurred  in  developed  countries  (456,000  cases  in  men;
21,000  in  women)  and  half  of  those  cases  were  on  the  Asian
ontinent  (mainly  China)2
For  the  year  2011  in  Mexico,  gastric  cancer  was  among
he  main  causes  of  hospital  morbidity  in  men,  with  the  high-
st  rate  in  the  75  to  79-year-old  population  (47  of  every
00,000  men  in  that  age  group),  followed  by  the  65  to  74-
ear-old  population  (38  of  every  100,000  men  of  that  age
roup).  It  is  currently  known  that  of  the  main  malignant
umors  causing  death  in  the  Mexican  population  of  20-year-
lds,  gastric  cancer  is  the  3rd  cause  in  both  women  (7%)
nd  men  (8.6%),  after  breast  cancer  (13.8%),  cervical  cancer
10.4%),  prostate  cancer  (16.9%),  and  bronchial/lung  cancer
12.8%),  respectively.3
p
c
dAccording  to  Lauren,  gastric  adenocarcinoma  is  a  het-
rogeneous  disease  that  is  histologically  divided  into
he  intestinal,  diffuse,  and  undifferentiated  non-mucus-
roducing  types,4 and  is  anatomically  classiﬁed  as  proximal
r  distal.5 More  recently,  genomic  and  molecular  clas-
iﬁcations  have  been  made,6--8 and  numerous  molecular
lterations  may  be  involved  in  each  histologic  subtype.
natomic  and  histologic  classiﬁcation  can  provide  knowl-
dge  about  tumor  biology  and  facilitate  the  selection  of  a
opulation  to  receive  targeted  therapies.9
Gastric  cancer  development  is  a  multifactorial  and  com-
lex  process  with  a lengthy  progression.  It  is  very  unlikely
hat  infection  by  Helicobacter  pylori  alone  is  responsible
or  the  development  of  gastric  cancer.  There  is  evidence
hat  the  consumption  of  salty  foods,  N-nitroso  compounds,
nd  a  low  consumption  of  fresh  fruit  and  vegetables  increase
he  risk  for  gastric  cancer.10
Intestinal-type  adenocarcinoma  is  associated  with  severe
trophic  chronic  gastritis,  intestinal  metaplasia,  and  dys-
lasia.  It  corresponds  to  well  or  moderately  differentiated
arcinomas,  and  is  characterized  by  the  formation  of  glan-
ular  cells  similar  to  intestinal  cells.  It  is  mainly  situated
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aClinical  and  pathologic  characteristics  of  gastric  adenocarci
in  the  antrum  and  settles  in  zones  of  previous  intestinal
metaplasia,  especially  of  the  colonic  or  incomplete  type.11
Diffuse-type  adenocarcinoma  encompasses  the  inﬁltrative
variety  and  is  poorly  differentiated,  with  the  presence
of  signet  ring  cells  and  without  apparent  gastritis.  It  is
thought  to  appear  de  novo  and  is  associated  with  low  CDHI
regulation.12 There  are  no  epidemiologic  studies  on  the
Mexican  population  that  classify  gastric  adenocarcinoma
by  histologic  subtype,  in  the  knowledge  that  each  subtype
behaves  differently.
The  aim  of  this  study  was  to  determine  the  frequency
of  gastric  adenocarcinoma  and  compare  the  histopatho-
logic  characteristics  of  its  subtypes  reported  at  the  Hospital
Juárez  de  México  (a  tertiary  care  center)  over  the  last
10  years.
Methods
Patients
A  retrospective  and  conﬁdential  database  was  elaborated
in  relation  to  all  the  patients  with  gastric  adenocarci-
noma  diagnosed  within  the  time  frame  of  January  2003  and
December  2012  at  the  Hospital  Juárez  de  México. Histo-
logic  conﬁrmation  was  performed  by  the  hospital’s  Pathology
Department.  Other  tumors,  such  as  lymphomas,  sarcomas,
and  neuroendocrine,  gastric  cardia,  and  gastroesophageal
junction  tumors  were  excluded  from  the  analysis.  The  study
included  patients  above  the  age  of  18  years.
Study  design
Patient  medical  records  were  reviewed  to  obtain  the  fol-
lowing  data  that  included  age  at  the  time  of  diagnosis,  sex,
tumor  location  (only  including  those  located  in  the  body,
antrum,  and  pylorus),  and  histologic  subtypes  based  on  the
Lauren  classiﬁcation.  The  type  of  sample  (biopsy  or  gas-
trectomy)  was  speciﬁed,  along  with  differentiation  grade,
inﬁltration  grade,  and  the  presence  of  ulceration,  lymph
node  invasion,  perineural  and  angioinvasion,  surgical  mar-
gins,  and  Helicobacter  pylori.
Statistical  analysis
A  retrospective  study  was  conducted  that  covered  a  10-
year  time  period.  The  Windows  SPSS  program  was  used
for  the  statistical  analysis  and  the  continuous  variables
were  expressed  as  means  and  dispersion  coefﬁcients  were
used  for  standard  deviation.  Frequencies  were  expressed  as
percentages  and  the  categorical  variables  were  compared
utilizing  the  chi-square  test.  Statistical  signiﬁcance  was  set
at  a  p  <  0.05.
Results
A  total  of  417  cases  of  gastric  adenocarcinoma  were
found.  Three  hundred  and  thirty-four  (80%)  of  them
were  obtained  through  endoscopic  biopsy  and  83  (20%)
through  gastrectomy  (51  partial,  26  total,  and  6  not
speciﬁed).  Diffuse-type  adenocarcinoma  was  reported  in
t
s
m
t in  Mexican  patients  23
30  patients  (55.2%),  intestinal-type  in  118  patients  (28.2%),
nd  undifferentiated-type  in  25  patients  (6%);  sub-type  was
ot  determined  in  44  patients  (10.6%)  (ﬁgure  1).  The  mean
ge  for  the  diffuse-type  patients  was  54.02  ±  14.93  and  118
f  those  patients  (51.3%)  were  men.  The  mean  age  for  the
atients  with  the  intestinal  type  was  63.43  ±  13.78,  and  69
62.2%)  were  men.
The  diffuse  type  had  a  statistically  signiﬁcant  associa-
ion  in  relation  to  the  number  of  cases  in  patients  <  50  years
f  age  (p  <  0.001),  perineural  invasion  (p  =  0.5),  positive  sur-
ical  margins  (p  <  0.5),  and  positive  angioinvasion  (p  <  0.5).
Among  the  diffuse-type  patients,  92  were  under  50  years
f  age,  compared  with  22  patients  with  intestinal-type  car-
inoma  (ﬁgure  2).
iscussion
nalyzing  the  histologic  subtypes  of  gastric  adenocarcinoma
n  patients  diagnosed  over  the  last  10  years  at  the  Hospi-
al  Juárez  de  México, the  diffuse-type  was  observed  to  be
he  most  prevalent,  presenting  in  one-third  of  the  patients
nder  50  years  of  age.
There  are  no  studies  in  Mexico  that  classify  adenocarci-
oma  by  subtype  or  anatomic  location.  In  a  study  by  Bonequi
t  al.,13 they  carried  out  a  search  of  the  PubMed  database
nd  reported  that  in  9  out  of  20  Latin  American  countries,
ncluding  Mexico,  the  histologic  gastric  adenocarcinoma
ubtype  encountered  was  the  intestinal-type  in  the  distal
ocation  (ﬁgure  3).  There  are  high  incidence  rates  of  gastric
ancer  in  Latin  America,  but  the  reasons  for  this  are  not  yet
nown.  Convincing  data  suggest  environmental  factors  and
ertain  diseases,  such  as  atrophic  gastritis,14 adenomatous
olyps,15 dysplasia,16 metaplasia,17 Ménétrier’s  disease,18
nd  pernicious  anemia.19 Also  included  are  nutritional  fac-
ors,  such  as  high  salt  intake  and  the  consumption  of  smoked
oods,  spicy  foods,  nitrite-rich  foods,  foods  high  in  carbohy-
rates  and  fat,  and  the  low  consumption  of  milk,  fresh  fruit
nd  vegetables,  selenium,  and  vitamins  A,  C,  and  E.20 High
obacco  and  alcohol  consumption  as  risk  factors  for  gastric
ancer  are  still  a  subject  of  debate.21,22
Numerous  researchers  have  reported  a  worse  prognosis
or  patients  with  proximal  cancer  than  those  with  cancer
hat  is  located  in  the  mid  and  distal  regions  of  the  stomach.23
espite  the  fact  that  the  global  incidence  of  gastric  cancer
ontinues  to  decrease,  the  incidence  of  proximal  and  gas-
roesophageal  junction  gastric  adenocarcinoma  in  the  U.S.
s  increasing.24,25
The  development  of  molecular  biology  has  improved  our
nderstanding  of  gastric  cancer,  even  though  its  molec-
lar  mechanisms  are  not  yet  known.  Some  interesting
olecules  have  been  suggested  as  prognostic  markers  in
hese  patients,  including  cell  adhesion  molecules.26 Mul-
iple  pathways  are  involved  in  different  subtypes:  human
pidermal  growth  factor  receptor  2  (HER2)27 and  epider-
al  growth  factor  receptor28 overexpression  predominate
n  non-diffuse  cancer.  Diffuse-type  gastric  cancer  is  char-
cterized  by  aberrant  cell  adhesion  (ﬁgure  4).  Cadherins,
ogether  with  catenins,  play  an  important  role  in  cell  adhe-
ion  and  polarity.29 Defects  in  the  APC  and  DCC  genes,
icrosatellite  instability,  and  promoter  hypermethylation  of
he  hMLH1  gene  have  been  associated  with  intestinal-type
24  M.G.  Martínez-Galindo  et  al.
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Figure  1  Number  of  cases  divided  by  sex  and  histologic  type.
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Figure  2  Number  of  cases  divided  by  age  group  and  histologic  type.
Figure  3  H&E  stain;  intestinal-type  adenocarcinoma.
Figure  4  H&E  stain;  adenocarcinoma  with  signet  ring  cells.
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gastric  cancer.30--33 Tumor  suppressing  genes,  such  as  p53,34
and  overexpression  of  the  epidermal  growth  factor  recep-
tor,  vascular  endothelial  growth  factor  receptor,  and  HER2
have  all  been  associated  with  poor  outcome.35,36 Targeted
therapies  combined  with  chemotherapy  have  produced
encouraging  results  in  the  treatment  of  patients  with
advanced  esophageal  and  gastric  cancer.37
Patients  of  different  racial  and  ethnic  groups,  whatever
their  origins,  have  different  natural  histories,  detection  and
treatment  access,  as  well  as  dissimilar  outcomes,  in  relation
to  numerous  diseases.38 These  variations  have  an  important
value  because  they  enable  the  identiﬁcation  of  biologic,
environmental,  and  socioeconomic  differences.  The  under-
standing  of  the  biologic  and  molecular  basis  of  gastric  cancer
can  facilitate  oncologic  therapy  adapted  to  the  individual
characteristics  of  each  speciﬁc  tumor.
Ours  is  the  ﬁrst  study  on  the  Mexican  population  to  high-
light  the  differences  between  the  histologic  subtypes  of
gastric  adenocarcinoma,  which  could  facilitate  the  selec-
tion  of  targeted  therapies.  The  most  frequent  gastric  cancer
subtype  in  our  population  was  the  diffuse-type,  which  is
associated  with  worse  outcome.  Up  to  one-third  of  the
patients  with  gastric  adenocarcinoma  were  under  the  age  of
50  years,  which  has  signiﬁcant  economic  implications.  The
histology,  sex,  and  age  at  time  of  presentation  justify  further
research  on  the  epidemiology,  pathogenesis,  and  molecular
biology  of  gastric  cancer  in  Mexico.
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